Cost Effectiveness of PD-L1-Based Test-And-Treat Strategy With Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
PharmacoEconomics - Open - Switzerland
doi 10.1007/s41669-019-00178-7
Full Text
Open PDFAbstract
Available in full text
Date
September 17, 2019
Authors
Publisher
Springer Science and Business Media LLC